0001140361-16-053978.txt : 20160218
0001140361-16-053978.hdr.sgml : 20160218
20160218175025
ACCESSION NUMBER: 0001140361-16-053978
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160210
FILED AS OF DATE: 20160218
DATE AS OF CHANGE: 20160218
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001445283
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-225-0096
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC
DATE OF NAME CHANGE: 20080916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PERRIGO SCIENCE ONE LTD.
CENTRAL INDEX KEY: 0001565579
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 161439207
BUSINESS ADDRESS:
STREET 1: TREASURY BUILDING,
STREET 2: LOWER GRAND CANAL STREET
CITY: DUBLIN
STATE: L2
ZIP: L2 2
BUSINESS PHONE: 353 1 709 4000
MAIL ADDRESS:
STREET 1: TREASURY BUILDING,
STREET 2: LOWER GRAND CANAL STREET
CITY: DUBLIN
STATE: L2
ZIP: L2 2
FORMER NAME:
FORMER CONFORMED NAME: Elan Science One Ltd
DATE OF NAME CHANGE: 20121228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PERRIGO CORP LTD.
CENTRAL INDEX KEY: 0000737186
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 161439208
BUSINESS ADDRESS:
STREET 1: TREASURY BUILDING,
STREET 2: LOWER GRAND CANAL ST
CITY: DUBLIN
STATE: L2
ZIP: L2 2
BUSINESS PHONE: 269-673-8451
MAIL ADDRESS:
STREET 1: 515 EASTERN AVENUE
CITY: ALLEGAN
STATE: MI
ZIP: 49010
FORMER NAME:
FORMER CONFORMED NAME: ELAN Corp Ltd
DATE OF NAME CHANGE: 20140818
FORMER NAME:
FORMER CONFORMED NAME: ELAN CORP LTD
DATE OF NAME CHANGE: 19840104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ELAN PHARMA INTERNATIONAL LTD.
CENTRAL INDEX KEY: 0001307004
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 161439209
BUSINESS ADDRESS:
STREET 1: TREASURY BUILDING,
STREET 2: LOWER GRAND CANAL STREET
CITY: DUBLIN
STATE: L2
ZIP: L2 2
BUSINESS PHONE: 269-673-8451
MAIL ADDRESS:
STREET 1: 515 EASTERN AVENUE
CITY: ALLEGAN
STATE: MI
ZIP: 49010
FORMER NAME:
FORMER CONFORMED NAME: Elan Pharma International LTD
DATE OF NAME CHANGE: 20041026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PERRIGO HOLDINGS LTD.
CENTRAL INDEX KEY: 0001323996
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 161439210
BUSINESS ADDRESS:
STREET 1: TREASURY BUILDING,
STREET 2: LOWER GRAND CANAL ST
CITY: DUBLIN
STATE: L2
ZIP: L2 2
BUSINESS PHONE: 269-673-8451
MAIL ADDRESS:
STREET 1: 515 EASTERN AVENUE
CITY: ALLEGAN
STATE: MI
ZIP: 49010
FORMER NAME:
FORMER CONFORMED NAME: Elan Holdings LTD
DATE OF NAME CHANGE: 20050415
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PERRIGO Co plc
CENTRAL INDEX KEY: 0001585364
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0627
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 161439211
BUSINESS ADDRESS:
STREET 1: TREASURY BUILDING
STREET 2: LOWER GRAND CANAL STREET
CITY: DUBLIN
STATE: L2
ZIP: L2 2
BUSINESS PHONE: 269-673-8451
MAIL ADDRESS:
STREET 1: 515 EASTERN AVENUE
CITY: ALLEGAN
STATE: MI
ZIP: 49010
FORMER NAME:
FORMER CONFORMED NAME: PERRIGO Co Ltd
DATE OF NAME CHANGE: 20130828
4
1
doc1.xml
FORM 4
X0306
4
2016-02-10
0
0001445283
PROTEOSTASIS THERAPEUTICS, INC.
PTI
0001585364
PERRIGO Co plc
TREASURY BUILDING
LOWER GRAND CANAL STREET
DUBLIN
L2
2
IRELAND
0
0
1
0
0001323996
PERRIGO HOLDINGS LTD.
TREASURY BUILDING,
LOWER GRAND CANAL STREET
DUBLIN
L2
2
IRELAND
0
0
1
0
0001307004
ELAN PHARMA INTERNATIONAL LTD.
TREASURY BUILDING,
LOWER GRAND CANAL STREET
DUBLIN
L2
2
IRELAND
0
0
1
0
0000737186
PERRIGO CORP LTD.
TREASURY BUILDING,
LOWER GRAND CANAL ST
DUBLIN 2
L2
2
IRELAND
0
0
1
0
0001565579
PERRIGO SCIENCE ONE LTD.
TREASURY BUILDING,
LOWER GRAND CANAL STREET
DUBLIN
L2
2
IRELAND
0
0
1
0
Common Stock
2016-02-17
4
C
0
2416612
A
2416612
I
See footnote
Common Stock
2016-02-17
4
C
0
366455
A
2783067
I
See footnote
Common Strock
2016-02-17
4
P
0
125000
8.00
A
2908067
I
See footnote
Series A Convertible Redeemable Preferred Stock
2016-02-17
4
C
0
20000000
0
D
Common Stock
2416612
0
I
See footnote
Series B Convertible Redeemable Preferred Stock
2016-02-17
4
C
0
3961459
0
D
Common Stock
366455
0
I
See footnote
Stock Option (Right to Buy)
8
2016-02-10
4
A
0
45760
0
A
2016-02-10
Common Stock
45760
45760
I
See footnote
The Series A Convertible Redeemable Preferred Stock (the "Series A Shares") automatically converted on a 10.8102-to-1 basis into the Issuer's Common Stock, together with the accrued but unpaid dividends, upon closing of the Issuer's initial public offering into 2,416,612 shares of the Issuer's Common Stock. The Series A Shares did not have an expiration date.
The Series B Convertible Redeemable Preferred Stock (the "Series B Shares") automatically converted on a 10.8102-to-1 basis into the Issuer's Common Stock upon closing of the Issuer's initial public offering into 366,455 shares of the Issuer's Common Stock. The Series B Shares did not have an expiration date.
Perrigo Science One Ltd. ("Science") (formerly Elan Science One Ltd.) is the direct owner of these securities. Science is a direct or indirect, wholly-owned subsidiary of each of the other reporting persons.
These securities were purchased in connection with the initial public offering of the Issuer.
These securities shall vest and become exercisable in equal quarterly installments starting on February 10, 2016 until the option is fully vested and exercisable on February 10, 2019, subject to continued service.
Perrigo Company plc ("Perrigo") and the other reporting persons named herein may be deemed to beneficially own the 45,760 options granted to Mr. Walshe in his capacity as a director of Proteostasis Therapeutics, Inc. (the "Company"). Mr. Walshe has an understanding with Perrigo pursuant to which he holds such securities for the benefit of Perrigo.
/s/Todd Kingma, Secretary of Perrigo Company plc
2016-02-18
/s/Todd Kingma, Secretary of Perrigo Holdings Ltd.
2016-02-18
/s/Todd Kingma, Director of Elan Pharma International Limited
2016-02-18
/s/Todd Kingma, Secretary of Perrigo Corporation Limited
2016-02-18
/s/Todd Kingma, Secretary of Perrigo Science One Ltd.
2016-02-18